Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/75281
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oguiza, Ainhoa | en_US |
dc.contributor.author | Recio Cruz, Carlota Pilar | en_US |
dc.contributor.author | Lazaro, Iolanda | en_US |
dc.contributor.author | Mallavia, Beñat | en_US |
dc.contributor.author | Blanco, Julia | en_US |
dc.contributor.author | Egido, Jesus | en_US |
dc.contributor.author | Gomez-Guerrero, Carmen | en_US |
dc.date.accessioned | 2020-11-09T16:26:00Z | - |
dc.date.available | 2020-11-09T16:26:00Z | - |
dc.date.issued | 2015 | en_US |
dc.identifier.issn | 0012-186X | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/75281 | - |
dc.description.abstract | Aims/hypothesis The canonical nuclear factor-κB (NF-κB) pathway mediated by the inhibitor of NF-κB kinase (IKK) regulates the transcription of inflammatory genes involved in the pathogenesis of diabetes, from the early phase to progression and final complications. The NF-κB essential modulator binding domain (NBD) contained in IKKα/β is essential for IKK complex assembly. We therefore investigated the functional consequences of targeting the IKK-dependent NF-κB pathway in the progression of diabetes-associated nephropathy and atherosclerosis. Methods Apolipoprotein E-deficient mice with diabetes induced by streptozotocin were treated with a cell-permeable peptide derived from the IKKα/β NBD region. Kidneys and aorta were analysed for morphology, leucocyte infiltrate, collagen, NF-κB activity and gene expression. In vitro studies were performed in renal and vascular cells. Results NBD peptide administration did not affect the metabolic severity of diabetes but resulted in renal protection, as evidenced by dose-dependent decreases in albuminuria, renal lesions (mesangial expansion, leucocyte infiltration and fibrosis), intranuclear NF-κB activity and proinflammatory and pro-fibrotic gene expression. Furthermore, peptide treatment limited atheroma plaque formation in diabetic mice by decreasing the content of lipids, leucocytes and cytokines and increasing plaque stability markers. This nephroprotective and anti-atherosclerotic effect was accompanied by a decline in systemic T helper 1 cytokines. In vitro, NBD peptide prevented IKK assembly/activation, p65 nuclear translocation, NF-κB-regulated gene expression and cell proliferation induced by either high glucose or inflammatory stimulation. Conclusions/interpretation Peptide-based inhibition of IKK complex formation attenuates NF-κB activation, suppresses inflammation and retards the progression of renal and vascular injury in diabetic mice, thus providing a feasible approach against diabetes inflammatory complications. | en_US |
dc.language | eng | en_US |
dc.relation | SAF2012-38830 | en_US |
dc.relation | PI14/00386 | en_US |
dc.relation | PIE13/00051 | en_US |
dc.relation | FP7-HEALTH-2013-INNOVATION-1-602422 | en_US |
dc.relation.ispartof | Diabetologia (Berlin) | en_US |
dc.source | Diabetologia (Berlin), [ISSN 0012-186X], v. 58, p. 1656–1667 | en_US |
dc.subject | 320502 Endocrinología | en_US |
dc.subject.other | Atherosclerosis | en_US |
dc.subject.other | Diabetes | en_US |
dc.subject.other | Inflammation | en_US |
dc.subject.other | Nephropathy | en_US |
dc.subject.other | Nuclear factor-κB | en_US |
dc.subject.other | Peptide | en_US |
dc.title | Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1007/s00125-015-3596-6 | en_US |
dc.description.lastpage | 1667 | en_US |
dc.identifier.issue | 7 | - |
dc.description.firstpage | 1656 | en_US |
dc.relation.volume | 58 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.utils.revision | Sí | en_US |
dc.identifier.ulpgc | No | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 3,609 | |
dc.description.jcr | 6,206 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q1 | |
dc.description.scie | SCIE | |
item.grantfulltext | open | - |
item.fulltext | Con texto completo | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Clínicas | - |
crisitem.author.orcid | 0000-0002-8832-2826 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Recio Cruz, Carlota Pilar | - |
Appears in Collections: | Artículos |
WEB OF SCIENCETM
Citations
36
checked on Dec 15, 2024
Page view(s)
83
checked on Sep 23, 2023
Download(s)
94
checked on Sep 23, 2023
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.